DermNet provides Google Translate, a free machine translation service. Note that this may not provide an exact translation in all languages


Author: A/Prof Amanda Oakley, Dermatologist, Hamilton, New Zealand, 1997. Updated September 2014.

Melasma — codes and concepts

What is melasma?

Melasma is a chronic skin disorder that results in symmetrical, blotchy, brownish facial pigmentation. Melasma can also affect the arms and back. It can lead to considerable embarrassment and distress.

This form of facial pigmentation is sometimes called chloasma, but as this means green skin, the term melasma (brown skin) is preferred.

Melasma / chloasma

See more images of melasma.

Who gets melasma?

Melasma is more common in women than in men; only 1-in-4 to 1-in-20 affected individuals are male, depending on the population studied. It generally starts between the age of 20 and 40 years, but it can begin in childhood or not until middle age.

Melasma is more common in people that tan well or have naturally brown skin (Fitzpatrick skin types 3 and 4) compared with those who have fair skin (skin types 1 and 2) or black skin (skin types 5 or 6).

What causes melasma?

The cause of melasma is complex. The pigmentation is due to overproduction of melanin by the pigment cells, melanocytes, which is taken up by the keratinocytes (epidermal melanosis) and deposited in the dermis (dermal melanosis, melanophages). There is a genetic predisposition to melasma, with at least one-third of patients reporting other family members to be affected. In most people, melasma is a chronic disorder.

Known triggers for melasma include:

  • Sun exposure and sun damage — this is the most important avoidable risk factor. Visible light and ultraviolet rays contribute to abnormal pigmentation
  • Pregnancy — in affected women, the pigment often fades a few months after delivery
  • Hormone treatments — oral contraceptive pills containing oestrogen and progesterone, hormone replacement, intrauterine devices and implants are a factor in about a quarter of affected women
  • Certain medications (including new targeted therapies for cancer), scented or deodorant soaps, toiletries and cosmetics may cause a phototoxic reaction that triggers melasma, which may then persist long term
  • Hypothyroidism 

Melasma commonly arises in healthy, non-pregnant adults. Lifelong sun exposure causes deposition of pigment within the dermis, and this often persists long-term. Exposure to ultraviolet radiation (UVR) deepens the pigmentation because it activates the melanocytes to produce more melanin.

Research is attempting to pinpoint the roles of stem cell, neural, vascular and local hormonal factors in promoting melanocyte activation.

What are the clinical features of melasma?

Melasma presents as macules (freckle-like spots) and larger flat brown patches. These are found on both sides of the face and have an irregular border. There are several distinct patterns.

  • Centrofacial pattern: forehead, cheeks, nose and upper lips
  • Malar pattern: cheeks and nose
  • Lateral cheek pattern
  • Mandibular pattern: jawline
  • Reddened or inflamed forms of melasma (also called erythrosis pigmentosa faciei)
  • Poikiloderma of Civatte: reddened, photoaging changes are seen on the sides of the neck, mostly affecting patients older than 50 years
  • Brachial type of melasma affecting shoulders and upper arms (also called acquired brachial cutaneous dyschromatosis).

Melasma is sometimes separated into epidermal, dermal, and mixed types. A Wood lamp that emits black light (UVA1) may be used to identify the depth of the pigment.

Epidermal melasma

  • Well-defined border
  • Dark brown colour
  • Appears more obvious under black light
  • Responds well to treatment

Dermal melasma

  • Ill-defined border
  • Light brown or bluish
  • Unchanged under black light
  • Responds poorly to treatment

Mixed melasma

  • The most common type
  • Combination of bluish, light and dark brown patches
  • A mixed pattern is seen under black light
  • Partial improvement with treatment

How is melasma diagnosed?

The characteristic appearance of melasma means the diagnosis is usually straightforward and made clinically. Other disorders that may be considered instead of melasma or as well as melasma include:

Occasionally, a skin biopsy may be performed to make or confirm the diagnosis of melasma. Histology varies with the type of melasma. But some degree of each of the following features is usually found.

  • Melanin deposited in basal and suprabasal keratinocytes
  • Highly dendritic (branched) intensely pigmented melanocytes
  • Melanin in the dermis within melanophages
  • Solar elastosis and elastic fibre fragmentation

The extent and severity of melasma can be described using the Melasma Area and Severity Index (MASI).

What is the treatment of melasma?

Melasma can be very slow to respond to treatment, especially if it has been present for a long time. Treatment may result in irritant contact dermatitis in patients with sensitive skin, and this can result in post-inflammatory pigmentation.

Generally, a combination of the following measures is helpful.

General measures

  • Discontinue hormonal contraception.
  • Year-round life-long sun protection. Wear a broad-brimmed hat.
  • Use broad-spectrum very high protection factor (SPF 50+) sunscreen applied to the whole face daily, year-round. It should be reapplied every 2 hours if outdoors during the summer months. Sunscreens containing iron oxides are preferred, as they screen out some visible light as well as ultraviolet radiation. Alternatively or as well, use a make-up that contains sunscreen.  
  • Use a mild cleanser, and if the skin is dry, a light moisturiser.
  • Cosmetic camouflage (make-up) is invaluable to disguise the pigment.

Topical therapy

Tyrosinase inhibitors are the mainstay of treatment. The aim is to prevent new pigment formation by inhibiting the formation of melanin by the melanocytes.

  • Hydroquinone 2–4% as cream or lotion, applied accurately to pigmented areas at night for 2–4 months. This may cause contact dermatitis (stinging and redness) in 25% of patients. It should not be used in higher concentration or for prolonged courses as it has been associated with ochronosis (a bluish grey discolouration similar to that seen in alkaptonuria).
  • Azelaic acid cream, lotion or gel can be applied twice daily long term and is safe in pregnancy. This may also sting.
  • Kojic acid or kojic acid dipalmitate is often included in formulations, as it binds copper, required by L-DOPA (a cofactor of tyrosinase). Kojic acid can cause irritant contact dermatitis and less commonly, allergic contact dermatitis.
  • The mechanism of action of cysteamine cream is unclear but is thought to involve inhibition of tyrosinase. A study of 50 patients with melasma found cysteamine cream to be significantly more effective than a placebo cream.
  • Ascorbic acid (vitamin C) also acts through copper to inhibit pigment production. It is well tolerated but highly unstable, so is usually combined with other agents.
  • Methimazole (antithyroid drug) cream has been reported to reduce melanin synthesis and pigmentation in hydroquinone-resistant melasma.
  • New agents under investigation include zinc sulfate mequinol, arbutin and deoxyarbutin (from berries), liquorice extract, rucinol, resveratrol, 4-hydroxy-anisole, 2,5-dimethyl-4-hydroxy-3(2H)-furanone and/or N-acetyl glucosamine

Other active compounds used for melasma include:

  • Topical corticosteroids such as hydrocortisone. These work quickly to fade the colour and reduce the likelihood of contact dermatitis caused by other agents. Potent topical steroids are best avoided due to their potential to cause adverse effects.
  • Soybean extract, which is thought to reduce the transfer of pigment from melanocytes to skin cells (keratinocytes) and to inhibit receptors.
  • Tranexamic acid has been used experimentally for melasma as a cream or injected into the skin (mesotherapy), showing some benefit. It may cause allergy or irritation.

The superficial or epidermal pigment can be peeled off. Peeling can also allow tyrosinase inhibitors to penetrate more effectively. These must be done carefully as peels may also induce post-inflammatory pigmentation.

The most successful formulation has been a combination of hydroquinone, tretinoin, and moderate potency topical steroid. This has been found to result in improvement or clearance in up to 60–80% of those treated. Many other combinations of topical agents are in common use, as they are more effective than a single agent. However, these products are often expensive.

Oral treatment of melasma

Oral medications for melasma are under investigation, including tranexamic acid. Tranexamic acid is a lysine analogue that inhibits plasmin and is usually used orally to stop bleeding. It reduces the production of prostaglandins, the precursors of tyrosine. In a low dose, tranexamic acid has been reported to be effective and safe in the treatment of melasma, providing patients have been carefully selected and are at low risk of thromboembolic disease.  

Glutathione is also under investigation as a systemic skin whitening agent but has potentially severe adverse effects.

Devices used to treat melasma

The ideal treatment for melasma would destroy the pigment while leaving the cells alone. Unfortunately, this is hard to achieve. Machines can be used to remove epidermal pigmentation, but with caution—over-treatment may cause postinflammatory pigmentation. Patients should be pretreated with a tyrosinase inhibitor (see above).

Fractional lasers, Q-switched Nd:YAG lasers, picosecond lasers and intense pulsed light (IPL) appear to be the most suitable options. Several treatments may be necessary, and post-inflammatory hyperpigmentation may complicate recovery.

Carbon dioxide or erbium:YAG resurfacing lasers, pigment lasers (Q-switched ruby and Alexandrite devices) and mechanical dermabrasion and microdermabrasion should be used with caution in the treatment of melasma.

What is the outcome of treatment of melasma?

Results take time, and the above measures are rarely entirely successful.

Unfortunately, even in those that get a good result from treatment, pigmentation may reappear on exposure to summer sun and because of hormonal and endogenous factors. New topical and oral agents are being studied and offer hope for effective treatments in the future.

See smartphone apps to check your skin.
[Sponsored content]


Related information



  • Vaneeta M. Sheth, Amit G. Pandya. Melasma: A comprehensive update Part I:Journal of the American Academy of DermatologyVolume 65, Issue 4, October 2011, Pages 689–697
  • Vaneeta M. Sheth, Amit G. Pandya. Melasma: A comprehensive update Part II Journal of the American Academy of Dermatology, Volume 65, Issue 4, October 2011, Pages 699-714
  • Gupta AK, Gover MD, Nouri K, Taylor S. The treatment of melasma: A review of clinical trials. J Am Acad Dermatol 2006;55:1048-65. PubMed.
  • Mansouri P, Farshi S, Hashemi Z, Kasraee B. Evaluation of the efficacy of cysteamine 5% cream in the treatment of epidermal melasma: a randomized double-blind placebo-controlled trial. Br J Dermatol. 2015 Jul;173(1):209-17. doi: 10.1111/bjd.13424. PubMed PMID: 25251767. PubMed.
  • Kim HJ, Moon SH, Cho SH, Lee JD, Kim HS. Efficacy and Safety of Tranexamic Acid in Melasma: A Meta-analysis and Systematic Review. Acta Derm Venereol. 2017 Apr 4. doi: 10.2340/00015555-2668. [Epub ahead of print] PubMed PMID: 28374042. Journal.
  • Del Rosario E, Florez-Pollack S, Zapata L Jr et al. Randomized, placebo-controlled, double-blind study of oral tranexamic acid in the treatment of moderate to severe melasma. J
    Am Acad Dermatol. 2017 Oct 4. pii: S0190-9622(17)32458-1. doi: 10.1016/j.jaad.2017.09.053. [Epub ahead of print] PubMed PMID: 28987494. Journal.

DermNet NZ

Other websites

Books about the skin

See the DermNet NZ bookstore.